Regulatory & Safety Aspects of Cell & Gene Therapy

Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

    Related Conference of Regulatory & Safety Aspects of Cell & Gene Therapy

    October 17-18, 2022

    21st International Conference on Structural Biology

    Barcelona, Spain
    November 15-16, 2022

    3rd Experts Meeting on Plant, Cellular and Molecular Biology

    Budapest, Hungary
    November 21-22, 2022

    4th Annual summit on Cell Signaling and Cancer Therapy

    Montreal, Canada
    May 03-04, 2023

    16th World Congress on Stem Cell Research

    Paris, France
    May 03-04, 2023

    Global Conference on Cell and Gene Therapy

    Paris, France

    Regulatory & Safety Aspects of Cell & Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in